Cite
HARVARD Citation
Cao, Z. et al. (2020). Erlotinib is effective against FLT3‐ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn. FASEB journal. 34 (8), pp. 10182-10190. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Cao, Z. et al. (2020). Erlotinib is effective against FLT3‐ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn. FASEB journal. 34 (8), pp. 10182-10190. [Online].